Sandra Karanović Štambuk

Dr. Sandra Karanović Štambuk

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
MAMaude Ardin
Maude Ardin
ZTZuojian Tang
Zuojian Tang
KTKarla Tomić
Karla Tomić
SVStephanie Villar
Stephanie Villar
JZJiri Zavadil
Jiri Zavadil
Recurrent upper tract urothelial carcinomas (UTUCs) arise in the context of nephropathy linked to exposure to the herbal carcinogen aristolochic acid (AA). Here we delineated the molecular programs underlying UTUC tumorigenesis in patients from endemic aristolochic acid nephropathy (AAN) regions in Southern Europe. We applied an integrative multiomics analysis of UTUCs, corresponding unaffected tissues and of patient urines. Quantitative microRNA (miRNA) and messenger ribonucleic acid (mRNA) expression profiling, immunohistochemical analysis by tissue microarrays and exome and transcriptome sequencing were performed in UTUC and nontumor tissues. Urinary miRNAs of cases undergoing surgery were profiled before and after tumor resection. Ribonucleic acid (RNA) and protein levels were analyzed using appropriate statistical tests and trend assessment. Dedicated bioinformatic tools were used for analysis of pathways, mutational signatures and result visualization. The results delineate UTUC‐specific miRNA:mRNA networks comprising 89 miRNAs associated with 1,862 target mRNAs, involving deregulation of cell cycle, deoxyribonucleic acid (DNA) damage response, DNA repair, bladder cancer, oncogenes, tumor suppressors, chromatin structure regulators and developmental signaling pathways. Key UTUC‐specific transcripts were confirmed at the protein level. Exome and transcriptome sequencing of UTUCs revealed AA‐specific mutational signature SBS22, with 68% to 76% AA‐specific, deleterious mutations propagated at the transcript level, a possible basis for neoantigen formation and immunotherapy targeting. We next identified a signature of UTUC‐specific miRNAs consistently more abundant in the patients' urine prior to tumor resection, thereby defining biomarkers of tumor presence. The complex gene regulation programs of AAN‐associated UTUC tumors involve regulatory miRNAs prospectively applicable to noninvasive urine‐based screening of AAN patients for cancer presence and recurrence.

26 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
PPPaula Polenus
Paula Polenus
ADAna Duran
Ana Duran
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
Chronic kidney disease (CKD) is a global health challenge, marked by significant morbidity and mortality and a rising economic burden. Despite established therapies such as renin–angiotensin system (RAS) inhibitors and SGLT2 inhibitors, a substantial residual risk of CKD progression and cardiovascular events persists. This gap is largely attributed to the sustained overactivation of the mineralocorticoid receptors by aldosterone, a key driver of renal inflammation and fibrosis. This review aims to bridge the understanding between aldosterone’s intricate pathophysiology and emerging therapeutic strategies designed to address this unmet clinical need. We discuss the physiological regulation of aldosterone synthesis and secretion, the phenomenon of aldosterone breakthrough under conventional RAS blockade and the diverse mechanisms through which aldosterone mediates kidney damage. We evaluate novel non-steroidal mineralocorticoid receptor antagonists, exemplified by finerenone, which demonstrate superior safety profiles and valid efficacy in reducing renal and cardiovascular outcomes in clinical trials. Additionally, we examine aldosterone synthase inhibitors as an upstream therapeutic approach to directly reduce aldosterone production. These novel agents represent promising avenues to mitigate residual risk and improve long-term outcomes for patients with CKD.

23 May 2024 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
Introduction: Primary aldosteronism (PA), a common secondary cause of arterial hypertension, is treated either surgically or pharmacologically with mineralocorticoid receptor antagonists (MRAs). These drugs, while effective, can cause allergic reactions and have side effects, including menstrual cycle disorders in women. Finerenone is a new, highly selective, nonsteroidal MRA with excellent side-effect profile, primarily intended to slow the progression of diabetic kidney disease and improve cardiovascular outcomes in these patients. No data are available so far on its effect on patients with PA. Case Presentation: A case of a female patient with confirmed primary aldosteronism, in whom adrenal vein sampling failed twice is presented. The patient developed a skin allergic reaction to spironolactone and experienced prolonged vaginal bleedings with eplerenone, which was attributed to the drug’s affinity for progesterone receptors. A trial of finerenone was initiated, resulting in mild increase in plasma renin activity and serum potassium, and somewhat control of blood pressure, but far from optimal blood pressure control, normokalemia, or unsuppression of plasma renin activity. Conclusion: This case highlights the challenges of managing PA and describes an attempt of treatment with finerenone to which this patient unfortunately did not adequately respond.

16 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
TDTea Delic
Tea Delic
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
Iodine is an essential micronutrient required for the synthesis of thyroid hormones and the maintenance of metabolic, neurodevelopmental and immune function. As iodine cannot be synthesized endogenously, adequate intake depends on dietary sources and environmental availability. Despite decades of progress in improving iodine supply, both iodine deficiency and excess remain significant global public health challenges. This review summarizes iodine physiology, covering both its role in thyroid hormone synthesis and emerging evidence for extrathyroidal immunomodulatory and antioxidant actions. It summarizes major dietary sources, global intake patterns and current approaches to iodine status assessment, including urinary biomarkers, salivary iodide measurement and dietary screening tools. The clinical consequences of iodine imbalance are examined, ranging from goiter, hypothyroidism and impaired neurocognitive development associated with deficiency, to iodine-induced thyroid dysfunction, autoimmunity and adverse systemic effects linked to excess intake. Special attention is given to vulnerable populations, particularly pregnant women and infants. This review further evaluates public health strategies, including salt iodization and targeted supplementation, while addressing the emerging challenge posed by salt-reduction initiatives. Achieving optimal iodine intake remains essential for thyroid health and population well-being, underscoring the need for coordinated monitoring and policy adaptation.

1 May 2024 in Journal Of Hypertension
Verified
Journal Article
Closed access
MMMatea Mustedanagic
Matea Mustedanagic
KPKristina Paponja
Kristina Paponja
BJBojan Jelakovic
Bojan Jelakovic
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
Objective: Glomerular diseases (GD) are strongly associated with arterial hypertension (AH). Increased blood pressure(BP) contributes to the pathogenesis and progression of kidney damage and impacts patients’ outcomes and overall morbidity and mortality. Our aim was to analyse the prevalence and control of AH among patients with GD hospitalized for native kidney biopsy. Design and method: This retrospective analyses included 189 consecutive subjects who underwent kidney biopsy during a 5-year period(2015-2019). The patients were grouped according to the presenting clinical syndrome: rapidly progressive glomerulonephritis (RPGN), nephritic syndrome(NiS), nephrotic syndrome(NS), chronic azotaemia+/-erythrocyturia/proteinuria (CA), syndrome of asymptomatic erythrocyturia+/- proteinuria (AEP). Data on office BP values measured according to the ESH guidelines upon admission as well as other clinical and laboratory values were collected from medical records. Results: Median BP value for the whole group was 140/85 (100-220/56-114) mmHg. AH was present in 98.9% of all patients. 77.0% were treated and BP control was achieved in 43.1% treated patients, while resistant hypertension was present in 23.6%. Median number of medications was 2 (0-6) with predominance of RAAS blockers (49,7%), CCBs (44,4%) and loop diuretics (33,8%). The subgroup data are shown in Table 1. Important statistically significant correlation of both systolic and diastolic BP with proteinuria (rho = 0.327, p < 0.001, rho = 0.237, p = 0.002) and eGFR (rho = - 0.298, p < 0.001, rho = - 0.224, p= 0.002) was found in the whole group. Conclusions: High prevalence of AH, low rates of its’ control partially due to therapeutic inertia and 23,6% of resistant hypertension was found among our patients with glomerular diseases. BP was associated with severity of kidney damage and proteinuria. We observed a difference with regards to the clinical presentation which necessitates further investigation with inclusion of ABPM findings.

Verified
Journal Article
Open access
PDF file
JHJakov Herceg
Jakov Herceg
GVGorana Vukorepa
Gorana Vukorepa
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
Background: Primary aldosteronism is characterized by elevated aldosterone levels, leading to adverse effects such as hypertension, hypokalaemia and increased risk for cardiovascular and cerebrovascular events. Aldosterone impacts the central nervous system by promoting vascular remodelling and oxidative stress, potentially impairing cognitive function. The presence of mineralocorticoid receptors in the hippocampus, a key region for cognition, further suggest a link between primary aldosteronism and cognitive dysfunction. This study aims to further explore the association between hyperaldosteronism and cognitive impairment. Methods: In this pilot study we examined 15 individuals with primary aldosteronism and arterial hypertension alongside 15 age- and sex-matched controls with essential hypertension, all free of previous cerebrovascular events. Clinical and archival laboratory data were obtained. Cognitive function was assessed using the Mini-Mental State Examination and Montreal Cognitive Assessment. Results: Participants with primary aldosteronism had higher blood pressure values, longer duration of hypertension, lower serum potassium levels and higher 24 h urine albumin excretion rate compared to controls. Comorbidities, other characteristics and laboratory values were comparable across the two groups. No differences were observed in Mini-Mental State Examination scores, but Montreal Cognitive Assessment scores were significantly lower in the primary aldosteronism group (25.1 ± 2.2 vs. 27.1 ± 2.2, p = 0.021). Trends of poorer performance in language and attention/executive function domains were noted in primary aldosteronism individuals, as well as a higher number of pathological Montreal Cognitive Assessment scores (7 vs. 3). No significant correlations were found between cognitive test results and aldosterone concentrations or blood pressure in primary aldosteronism group. However, importantly, multiple regression analysis showed that aldosterone levels have a significant impact on Montreal Cognitive Assessment test, independent of blood pressure or duration of hypertension. Conclusions: This study supports an association between hyperaldosteronism and cognitive dysfunction, underscoring the need for more active detection and targeted treatment of primary aldosteronism. These findings warrant further research in larger cohorts to better elucidate this relationship.